Monopril and Hyperviscosity syndrome - a phase IV clinical study of FDA data

Summary:

Hyperviscosity syndrome is reported as a side effect among people who take Monopril (fosinopril sodium), especially for people who are male, 60+ old, also take Alocril, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Hyperviscosity syndrome when taking Monopril. It is created by eHealthMe based on reports of 5,820 people who have side effects when taking Monopril from the FDA, and is updated regularly.

What is Monopril?

Monopril has active ingredients of fosinopril sodium. It is often used in high blood pressure. eHealthMe is studying from 5,910 Monopril users. Check the latest studies of Monopril.

What is Hyperviscosity syndrome?

Hyperviscosity syndrome (a condition in which blood is not able to flow freely through your arteries) is found to be associated with 53 drugs and 121 conditions by eHealthMe. Check the latest studies of Hyperviscosity syndrome.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

5,820 people reported to have side effects when taking Monopril.
Among them, 15 people (0.26%) have Hyperviscosity syndrome.

Could Monopril cause Hyperviscosity syndrome?

Among these 15 people:

What is the gender of people who have Hyperviscosity syndrome when taking Monopril? *

female: 0.0 %
male: 100 %

What is the age of people who have Hyperviscosity syndrome when taking Monopril? *

What are other drugs people take besides Monopril? *

What are other side effects people have besides Hyperviscosity syndrome? *

Weight Decreased: 15 people, 100.00%
Compression Fracture (fracture due to pressure caused by injury): 15 people, 100.00%
Nosebleed (bleeding from nose): 15 people, 100.00%
Metabolic Acidosis (body produces too much acid, or when the kidneys are not removing enough acid from the body): 15 people, 100.00%
Osteolysis (dissolution of bone): 15 people, 100.00%
Osteomyelitis (infection of bone): 15 people, 100.00%
Inflammation: 15 people, 100.00%
Hypoacusis (loss of hearing): 15 people, 100.00%
Hyperplasia (enlargement of an organ or tissue): 15 people, 100.00%
Gingival Bleeding (bleeding gums): 15 people, 100.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 14 people, 93.33%
Insomnia (sleeplessness): 3 people, 20.00%
Metastases To Bone (cancer spreads to bone): 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Monopril and have Hyperviscosity syndrome?

- Check whether Hyperviscosity syndrome is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Monopril:

Monopril (5,910 reports)

Browse all side effects of Monopril:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperviscosity syndrome:

Hyperviscosity syndrome (53 drugs)

Browse all the conditions that are associated with Hyperviscosity syndrome:

Hyperviscosity syndrome (121 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on fosinopril sodium (the active ingredients of Monopril) and Monopril (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.